XML 21 R8.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION Revenue Recognition (Notes)
 6 Months Ended
Jun. 30, 2020
Revenue Recognition [Abstract]  
Revenue from Contract with Customer [Text Block] REVENUE
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in Millions2020201920202019
Net product sales$9,817  $6,031  $20,358  $11,744  
Alliance revenues163  146  268  275  
Other revenues149  96  284  174  
Total Revenues$10,129  $6,273  $20,910  $12,193  

The following table summarizes GTN adjustments:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in Millions2020201920202019
Gross product sales$13,788  $8,819  $28,474  $16,813  
GTN adjustments(a)
Charge-backs and cash discounts(1,292) (890) (2,632) (1,664) 
Medicaid and Medicare rebates(1,482) (1,090) (2,980) (1,890) 
Other rebates, returns, discounts and adjustments(1,197) (808) (2,504) (1,515) 
Total GTN adjustments(3,971) (2,788) (8,116) (5,069) 
Net product sales$9,817  $6,031  $20,358  $11,744  
(a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $44 million and $116 million for the three and six months ended June 30, 2020 and $49 million and $127 million for the three and six months ended June 30, 2019, respectively.

The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in Millions2020201920202019
Prioritized Brands
Revlimid$2,884  $—  $5,799  $—  
Eliquis2,163  2,042  4,804  3,967  
Opdivo1,653  1,823  3,419  3,624  
Orencia750  778  1,464  1,418  
Pomalyst/Imnovid745  —  1,458  —  
Sprycel511  544  1,032  1,003  
Yervoy369  367  765  751  
Abraxane308  —  608  —  
Empliciti97  91  194  174  
Reblozyl55  —  63  —  
Inrebic15  —  27  —  
Zeposia1  —  1  —  
Established Brands
Baraclude121  147  243  288  
Vidaza126  —  284  —  
Other Brands(a)
331  481  749  968  
Total Revenues$10,129  $6,273  $20,910  $12,193  
United States$6,487  $3,667  $13,253  $7,116  
Europe2,136  1,491  4,703  2,971  
Rest of the World1,334  988  2,669  1,862  
Other(b)
172  127  285  244  
Total Revenues$10,129  $6,273  $20,910  $12,193  
(a) Includes BMS and Celgene products in 2020.
(b) Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.
Revenue recognized from performance obligations satisfied in prior periods was $98 million and $228 million for the three and six months ended June 30, 2020 and $117 million and $264 million for the three and six months ended June 30, 2019, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales. Contract assets were not material at June 30, 2020 and December 31, 2019.